Katholisches Kinderkrankenhaus Wilhelmstift gGmbH
- Address
- lock Available on a paid plan
Katholisches Kinderkrankenhaus Wilhelmstift gGmbH - Pediatric Dermatology & Rare Disease Research Center
Katholisches Kinderkrankenhaus Wilhelmstift gGmbH is a specialized pediatric research institution with demonstrated expertise in dermatological conditions and rare genetic disorders affecting children and adolescents. The center conducts advanced clinical trials focusing on novel therapeutic approaches for complex skin conditions and rare overgrowth syndromes, serving patients from early childhood through adolescence.
- Pediatric inflammatory skin conditions including moderate to severe plaque psoriasis, atopic dermatitis, and vitiligo
- Autoimmune hair loss disorders, specifically alopecia areata in children aged 6-17 years
- Rare genetic conditions such as PIK3CA-Related Overgrowth Spectrum (PROS)
- Pharmacokinetics and dose optimization studies for novel biologics and small molecule inhibitors in pediatric populations
The center demonstrates particular strength in evaluating JAK inhibitors, IL-17 antagonists, and TYK2 inhibitors across various dermatological and autoimmune conditions. Their research portfolio includes comprehensive assessment of both efficacy and long-term safety profiles of emerging therapies, with dedicated protocols examining pharmacokinetic parameters in age-stratified pediatric cohorts ranging from 4 to 18 years. The facility's experience with rare disease research, including PIK3CA-related disorders, highlights their capability in managing complex genetic conditions requiring specialized multidisciplinary care and precision medicine approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novartis Pharma AG1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Katholisches Kinderkrankenhaus Wilhelmstift gGmbH
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | May 2021 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alpelisib | 2 | Unknown | 2021-04-19 | 2025-12-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.